Clinical Trial

Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development

JERUSALEM, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the…

1 year ago

SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates

Raises combined $67.1M in private placement plus Tranche warrant exercise with syndicate of leading investors Received approval by the Human…

1 year ago

BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

SUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for…

1 year ago

atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights

Phase 2b study of RL-007 in CIAS patients continues to be on track to report data in 2H 2024 and…

1 year ago

HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights

MIRAMAR, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage…

1 year ago

Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024

LONDON and SALT LAKE CITY, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled…

1 year ago

Immatics Announces Third Quarter 2023 Financial Results and Business Update

ACTengine® IMA203 GEN1 TCR-T targeting PRAME showed 50% (6/12) confirmed ORR in melanoma patients with median duration of response (mDOR)…

1 year ago

Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Completed full enrollment and dosing of the 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial; based…

1 year ago

Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating potential strategic options…

1 year ago

Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update

Phase 1 clinical study of GT-02287 initiated; dosing escalation on scheduleBETHESDA, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics,…

1 year ago